Sakamakon gwajin rigakafin mura na COVID-19-Mura Yanzu Akwai

Novavax, Inc. a yau ta sanar da sakamakon farko daga gwaji na asibiti na Mataki na 1/2 na rigakafin cutar mura ta COVID-Influenza (CIC). CIC ta haɗa rigakafin Novavax' COVID-19, NVX-CoV2373, da ɗan takararta na rigakafin mura. Gwajin CIC ya nuna cewa samar da allurar haɗin gwiwar abu ne mai yuwuwa, jurewa da kuma rigakafi.            

Gregory M. Glenn, MD, Shugaban Bincike da Ci gaba, Novavax ya ce "Muna ci gaba da yin la'akari da yanayin yanayin lafiyar jama'a kuma mun yi imanin cewa za a iya buƙatar masu ƙarfafawa don yaƙar COVID-19 da mura na yanayi." "Waɗannan bayanan sun ƙarfafa mu da kuma yuwuwar hanyar da za a bi don haɗin gwiwar rigakafin mura na COVID-19 da kuma rigakafin rigakafin mura da COVID-19."

Bayanan aminci da juriya na haɗin gwiwar rigakafin ya yi daidai da tsayayyen NVX-CoV2373 da ƙayyadaddun bayanan rigakafin mura na nanoparticle a cikin gwajin. An gano hadewar rigakafin gabaɗaya da kyau. Mummunan mummunan abu ba safai ba ne kuma babu wanda aka tantance yana da alaƙa da maganin.

Binciken ya yi amfani da bayanan ƙarshe, kimanta aminci da martanin rigakafi na nau'ikan allurar CIC daban-daban. An yi amfani da Tsarin Tsarin Gwaje-gwaje (DOE) na tushen ƙirar ƙira don ƙira gwajin, yana ba da damar ingantaccen daidaitawa na zaɓin kashi na COVID-19 da antigens na mura don ƙarin haɓakawa idan aka kwatanta da hanyoyin gargajiya. Sakamakon gwaji na farko ya gano cewa nau'ikan alluran rigakafin CIC daban-daban sun haifar da martani na rigakafi a cikin mahalarta kwatankwacin yin la'akari da mura-kai kaɗai da ƙirar rigakafin COVID-19 (na H1N1, H3N2, B-Victoria HA da SARS-CoV-2 rS antigens) . Sakamakon samfurin ya kuma nuna cewa tsarin da aka haɗa yana da yuwuwar rage yawan adadin antigen har zuwa 50% gaba ɗaya, inganta samarwa da bayarwa.

Dukkanin alluran rigakafin furotin da aka yi amfani da su a cikin gwajin an ƙirƙira su tare da madaidaicin saponin na tushen Matrix-M™ adjuvant don haɓaka amsawar rigakafi da haɓaka manyan matakan rigakafin ƙwayoyin cuta. Waɗannan bayanan suna tallafawa ci gaba zuwa gwajin tabbatarwa na Mataki na 2, ana tsammanin farawa a ƙarshen 2022.

An gabatar da bayanai daga gwajin a taron Alurar riga kafi na Duniya (WVC) a Washington, DC.

Sabunta Shirin Mura 

A WVC, Novavax kuma ya sake nazarin mahimman abubuwan da aka samo daga gwaji na Phase 3 na ɗan takararta na mura, wanda a baya ake kira NanoFlu, wanda ya sadu da ƙarshen ƙarshen rigakafi na farko. An buga waɗannan sakamakon a baya a cikin The Lancet.

Izini a Amurka

Babu NVX-CoV2373 ko ɗan takarar rigakafin mura da aka ba da izini ko an amince da su don amfani a cikin Amurka ta Hukumar Abinci da Magunguna ta Amurka.

Muhimman Bayanan Tsaro don NVX-CoV2373

• An hana NVX-CoV2373 a cikin mutanen da ke da hypersensitivity ga abu mai aiki, ko ga kowane kayan haɓakawa.

An ba da rahoton abubuwan da suka faru na anaphylaxis tare da gudanar da allurar COVID-19. Ya kamata a sami jiyya da kulawa da ya dace idan an sami maganin anaphylactic bayan gudanar da maganin. An ba da shawarar kulawa kusa da aƙalla mintuna 15 kuma kada a ba da kashi na biyu na maganin ga waɗanda suka sami anaphylaxis zuwa kashi na farko na NVX-CoV2373.

• Abubuwan da ke da alaƙa da damuwa, ciki har da halayen vasovagal (syncope), hyperventilation, ko halayen da ke da alaka da damuwa na iya faruwa a hade tare da alurar riga kafi a matsayin martani na psychogenic ga allurar allura. Yana da mahimmanci cewa ana yin matakan kariya don guje wa rauni daga suma.

• Ya kamata a jinkirta yin rigakafin a cikin mutanen da ke fama da matsanancin ciwon zazzaɓi ko kamuwa da cuta mai tsanani. Kasancewar ƙaramin kamuwa da cuta da/ko ƙananan zazzabi bai kamata ya jinkirta yin rigakafin ba.

• Ya kamata a ba da NVX-CoV2373 tare da taka tsantsan a cikin mutanen da ke karɓar maganin rigakafin jijiyoyi ko waɗanda ke da thrombocytopenia ko kowace cuta ta coagulation (kamar haemophilia) saboda zubar jini ko ɓarna na iya faruwa bayan gudanarwar intramuscularly a cikin waɗannan mutane.

• Ingancin NVX-CoV2373 na iya zama ƙasa da ƙasa a cikin mutanen da aka hana rigakafi.

• Gudanar da NVX-CoV2373 a cikin ciki yakamata a yi la'akari da shi kawai lokacin da yuwuwar fa'idodin ya zarce duk wata haɗari ga uwa da tayi.

• Tasirin NVX-CoV2373 na iya yin tasiri na ɗan lokaci ikon tuƙi ko amfani da inji.

• Mutane ba za su sami cikakken kariya ba har sai kwanaki 7 bayan kashi na biyu. Kamar yadda yake tare da duk alluran rigakafi, allurar rigakafi tare da NVX-CoV2373 maiyuwa ba zai kare duk masu karɓar rigakafin ba.

• Mafi yawan halayen halayen da aka gani a lokacin nazarin asibiti sune ciwon kai, tashin zuciya ko amai, myalgia, arthralgia, wurin allura mai laushi / zafi, gajiya, da rashin lafiya.